Loading...
XHKG2269
Market cap9.18bUSD
Dec 23, Last price  
17.38HKD
1D
2.12%
1Q
35.15%
IPO
82.95%
Name

WuXi Biologics (Cayman) Inc

Chart & Performance

D1W1MN
XHKG:2269 chart
P/E
19.71
P/S
3.93
EPS
0.83
Div Yield, %
0.00%
Shrs. gr., 5y
1.99%
Rev. gr., 5y
46.38%
Revenues
17.03b
+11.56%
331,850,000557,042,000989,029,0001,618,829,0002,534,453,0003,983,687,0005,612,384,00010,290,050,00015,268,660,00017,034,255,000
Net income
3.40b
-23.09%
41,978,00044,509,000141,096,000252,628,000630,592,0001,013,805,0001,688,886,0003,388,478,0004,420,286,0003,399,729,000
CFO
4.67b
-15.77%
21,505,000107,150,00081,921,000360,280,000761,607,0001,208,079,0001,881,276,0003,431,258,0005,541,673,0004,667,712,000
Earnings
Mar 24, 2025

Profile

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
URL
https://www.wuxibiologics.com/
IPO date
Jun 13, 2017
Employees
12,397
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
17,034,255
11.56%
15,268,660
48.38%
10,290,050
83.35%
Cost of revenue
12,788,292
10,659,969
6,963,315
Unusual Expense (Income)
NOPBT
4,245,963
4,608,691
3,326,735
NOPBT Margin
24.93%
30.18%
32.33%
Operating Taxes
603,179
807,865
484,538
Tax Rate
14.21%
17.53%
14.56%
NOPAT
3,642,784
3,800,826
2,842,197
Net income
3,399,729
-23.09%
4,420,286
30.45%
3,388,478
100.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
(890,758)
(2,768,274)
8,518,194
BB yield
0.69%
1.06%
-2.08%
Debt
Debt current
731,308
1,470,488
2,225,456
Long-term debt
6,244,036
4,589,841
3,602,710
Deferred revenue
969,233
949,462
876,726
Other long-term liabilities
Net debt
(7,202,379)
(3,044,104)
(5,377,936)
Cash flow
Cash from operating activities
4,667,712
5,541,673
3,431,258
CAPEX
(4,045,574)
(5,868,390)
(6,523,114)
Cash from investing activities
(3,228,266)
(5,908,252)
(9,601,670)
Cash from financing activities
1,961,163
(2,591,592)
8,209,459
FCF
(213,837)
(2,932,842)
(5,226,011)
Balance
Cash
11,243,437
8,714,323
11,126,484
Long term investments
2,934,286
390,110
79,618
Excess cash
13,326,010
8,341,000
10,691,600
Stockholders' equity
21,938,243
14,111,051
8,178,784
Invested Capital
36,222,464
32,411,869
29,092,634
ROIC
10.62%
12.36%
11.61%
ROCE
8.55%
11.27%
8.90%
EV
Common stock shares outstanding
4,348,874
4,375,908
4,421,797
Price
29.60
-50.54%
59.85
-35.33%
92.55
-6.84%
Market cap
128,726,685
-50.85%
261,898,079
-36.00%
409,237,320
-2.14%
EV
126,702,667
260,019,645
404,286,957
EBITDA
5,415,339
5,409,365
3,808,518
EV/EBITDA
23.40
48.07
106.15
Interest
158,488
64,382
39,191
Interest/NOPBT
3.73%
1.40%
1.18%